Sonova (OTCMKTS:SONVY) Upgraded at BNP Paribas Exane

Sonova (OTCMKTS:SONVY) was upgraded by BNP Paribas Exane from a “strong sell” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

SONVY has been the subject of several other reports. Royal Bank Of Canada upgraded Sonova to a “moderate buy” rating in a research note on Tuesday, November 18th. Zacks Research upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Sonova Stock Performance

Shares of SONVY stock opened at $51.10 on Tuesday. The business has a fifty day moving average of $52.83 and a 200 day moving average of $53.77. Sonova has a 1 year low of $47.55 and a 1 year high of $68.76. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.91 and a current ratio of 1.24.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.